In recent years, multiple myeloma (hereafter referred to as myeloma, or MM) has risen to become the second most prevalent hematologic malignancy after lymphoma. However, due to the application of new tumor-targeting drugs such as Vanco, Renalidomide and Thalidomide, the survival of MM patients has been extended to 5-7 years, with some surviving for more than 10 years. It can already be considered a chronic disease like diabetes and hypertension. It is a malignant plasma cell disease that tends to occur in middle-aged and elderly people. Patients may be seen in orthopedics for bone diseases such as back and leg pain, bone pain, osteoporosis or paraplegia; or in nephrology for proteinuria and renal insufficiency; or in respiratory medicine for recurrent pneumonia; or in hematology for anemia; or in traditional Chinese medicine or physical therapy for various reasons. Almost every MM patient has a tortuous history of consultation. In my interactions with myeloma specialists at Mayo Hospital, I found that most of the MM patients in China had already progressed to a more advanced stage of the disease by the time they came to the hospital, and some had already developed paraplegia or uremia by the time they were seen, and the high incidence of advanced stages in Chinese MM patients was even unbelievable to American specialists. In fact, before these patients develop symptomatic MM and come to the hospital, their blood immunoglobulins may already be abnormal, manifested to varying degrees by elevated total globulin in biochemical tests, but without clinical manifestations, a stage known as monoclonal immunoglobulinemia of undetermined significance, abbreviated as MGUS. these MGUS patients may experience several years or even more than 20 years before developing Asymptomatic multiple myeloma, also known as smoldering myeloma (SMM), progresses to classic symptomatic myeloma. Therefore, MGUS is also known as the ancestral stage of myeloma, and SMM is the bridge stage connecting MGUS and MM. Our research on MGUS and SMM, the early stages of myeloma, is almost blank. For this reason, we have initiated early screening of myeloma by assaying fasting venous blood and 24-hour urine since the first half of 2015. In addition, it was found in the clinic that the 2 indicators of MM, serum albumin and β2 microglobulin, were related to the severity of disease and prognosis of myeloma patients; the lower the albumin and the higher the β2 microglobulin, the shorter the survival period and therefore the worse the prognosis. This is the international prognostic staging (ISS staging) of MM. In recent years, it has been found that patients with genetic abnormalities such as elevated lactate dehydrogenase and P53 deletion in blood have rapid disease progression and are prone to drug resistance and have a poor prognosis, so the International Myeloma Working Group has included these two indicators in the new revised international prognostic staging of MM in 2015, namely the R-ISS staging. In MM treatment, new tumor-targeted drugs have increased efficacy while placing higher demands on the depth of MM disease remission. It has been found that the amount of microscopic residual disease (MRD), a response to tumor load in the body, is 109 in MM patients at the time of symptomatic visits, and patients still have a significant amount of tumor residual MRD in their bodies when they achieve complete remission with treatment. The MRD was 102 or less when MRD-negative was achieved with continued treatment such as stem cell transplant consolidation and subsequent maintenance. It was found that MRD-negative patients had a longer survival and better prognosis than those who were positive. Therefore, the introduction of microscopic residual disease in MM places a higher demand on the efficacy and depth of remission. The conversion of patients to MRD after treatment has also become a goal for longer survival in subsequent patients. In addition, while our chemotherapy is striking myeloma tumor cells, tumor cells are evolving new tumor subclones to evade the strikes with new camouflage. Therefore, to design more new drugs to eliminate tumor subclones in early or late stages of tumor, to avoid their drug resistance and escape, and to prevent recurrence will also be the longer-term goal of anti-tumor drug design and research for a long time to come. Therefore, there are three highlights of the “New Advances in B Lymphoplasmacytic Neoplasm Course” in myeloma: (1) focus on the early stage of myeloma, such as we have started the early screening of MGUS and asymptomatic myeloma stage; (2) multidisciplinary joint: multidisciplinary joint consultation and cooperation among orthopedic, nephrology and hematology departments, etc. (3) The introduction of micro residual disease in myeloma treatment has put forward higher requirements on the depth of remission of myeloma, which will surely promote myeloma treatment to a higher level and prolong the survival of myeloma patients for a longer period for the benefit of patients and their families. At the same time, we would like to remind our middle-aged and elderly friends that if high globulin is found in biochemical or liver function tests during physical examination, or if back and leg pain or severe osteoporosis occur, or if unexplained proteinuria occurs in the urine, or if anemia occurs, especially if the above-mentioned manifestations are superimposed or combined, they should think about myeloma and visit the hematology department to help clarify the diagnosis. –Don’t miss this “invisible killer”.